Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents

Journal of Medical Economics

Volumn 15, Issue 6, 2012, Pages 1054-1063

  Gao, Xin ^a   Wendling, Daniel ^b   Botteman, Marc F ^a   Carter, John A ^a   Rao, Sumati ^c   Cifaldi, Mary ^c  

^a PHARMERIT INTERNATIONAL   (United States)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Ankylosing spondylitis; Anti TNF; Cost; Extra articular manifestation

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN A; DEXAMETHASONE; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; PREDNISOLONE; PREDNISOLONE ACETATE;

ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL FEATURE; ENTERITIS; EXTRAARTICULAR MANIFESTATION; FRANCE; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; IRIDOCYCLITIS; PSORIATIC ARTHRITIS; PSORIATIC SPONDYLITIS; REACTIVE ARTHRITIS; UNDIFFERENTIATED ANKYLOSING SPONDYLITIS; UVEITIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; FRANCE; GERMANY; HEALTH SERVICES; HUMANS; IMMUNOGLOBULIN G; INFLAMMATORY BOWEL DISEASES; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS, ANTERIOR;

EID: 84869784384     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.692341     Document Type: Article

References (47)

1. Elewaut D, Matucci-Cerinic M. Treatment of ankylosing spondylitis and extraarticular manifestations in everyday rheumatology practice. Rheumatology (Oxf) 2009;48:1029-35
2. Son JH, Cha SW. Anti-TNF-alpha therapy for ankylosing spondylitis. Clin Orthop Surg 2010;2:28-33
3. Mielants H, Van den BF. Extra-articular manifestations. Clin Exp Rheumatol 2009;27(Suppl. 55):S56-S61
4. Hamideh F, Prete PE. Ophthalmologic manifestations of rheumatic diseases. Semin Arthritis Rheum 2001;30:217-41
5. Rosenbaum JT, Smith Jr. Anti-TNF therapy for eye involvement in spondyloarthropathy. Clin Exp Rheumatol 2002;20(Suppl. 28):S143-S145
6. Braun J, Baraliakos X, Listing J, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007;57:639-47
7. Brandt J, Sieper J, Braun J. [Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNF alpha-antagonists]. Z Rheumatol 2003;62:218-27
8. Davis Jr JC, van der Heijde DM, Braun J, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008;67:346-52
9. van der HD, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46
10. Gorman JD, Sack KE, Davis Jr JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56
11. Inman RD, Davis Jr JC, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402-12
12. Kremer J, Ritchlin C, Mendelsohn A, et al. Golimumab, a new human antitumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010;62:917-28
13. Braun J, Baraliakos X, Listing J, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008;67:340-5
14. Grinblat B, Scheinberg M. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin Arthritis Rheum 2008;37:251-5
15. Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006;65:1631-4
16. Rudwaleit M, Rodevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009;68:696-701
17. Braun J, Sieper J. What is the most important outcome parameter in ankylosing spondylitis? Rheumatology (Oxf) 2008;47:1738-40
18. Sieper J, Koenig A, Baumgartner S, et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 2010; 69:226-9
19. Boonen A, van der HD, Landewe R, et al. Costs of ankylosing spondylitis in three European countries: the patient's perspective. Ann Rheum Dis 2003; 62:741-7
20. Jewell DP, Satsangi J, Lobo A, et al. Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005; 17:1047-52
21. Lloyd A, Reeves P, Conway P, et al. Economic evaluation of etanercept in the management of chronic plaque psoriasis. Br J Dermatol 2009;160:380-6
22. Tsai HH, Punekar YS, Morris J, et al. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-tosevere ulcerative colitis. Aliment Pharmacol Ther 2008;28:1230-9
23. Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006;131:719-28
24. Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51
25. Bonastre J, le Vaillant M, de Pouvourville G. The impact of research on hospital costs of care: an empirical study. Health Econ 2011;20(1):73-84
26. Lafuma A, Berdeaux G. Modelling lifetime cost consequences of ReSTOR in cataract surgery in four European countries. BMC Ophthalmol 2008;8:12
27. Losch A, Scheuerle A, Rupp V, et al. Transpalpebral measurement of intraocular pressure using the TGDc-01 tonometer versus standard Goldmann applanation tonometry. Graefes Arch Clin Exp Ophthalmol 2005;243:313-6
28. Martin J, Neurohr C, Bauer M, et al. [Cost of intensive care in a German hospital: cost-unit accounting based on the InEK matrix]. Anaesthesist 2008;57:505-12
29. Sohn S, Schoeffski O, Prinz J, et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 2006;212:137-44
30. Calin A, Dijkmans BA, Emery P, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594-600
31. Rolland N, Grandbastien B, Merle V, et al. [Cost of early management of chronic inflammatory intestinal disease]. Gastroenterol Clin Biol 1999;23: 483-8
32. Stark R, Konig HH, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics 2006;24:797-814
33. van der HD, Braun J, Landewe R, et al. ASessment in Ankylosing Spondylitis (ASAS) international working group: a model for psoriatic arthritis and psoriasis? Ann Rheum Dis 2005;64(2 Suppl):ii108-9
34. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904
35. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227-36
36. Baeten D, De KF, Mielants H, et al. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2002;16:537-49
37. Brophy S, Calin A. Ankylosing spondylitis: interaction between genes, joints, age at onset, and disease expression. J Rheumatol 2001;28:2283-8
38. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, doubleblind trial. Lancet 2005;366:1367-74
39. Evans TJ, Moyes D, Carpenter A, et al. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 1994;180:2173-9
40. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71
41. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-26
42. Baeten D, van Hagen PM. Use of TNF blockers and other targeted therapies in rare refractory immune-mediated inflammatory diseases: evidence-based or rational? Ann Rheum Dis 2010;69:2067-73
43. Wendling D, Paccou J, Bethelot JM, Flipo RM, Guillaume-Czitrom S, Prati C, Dernis E, Direz G, Ferrazzi V, Ristori JM, CRI; New onset of uveitis during antitumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011;41(3):503-10
44. Le GJ, Marcelli C, Mouriaux F. [Can tumor necrosis factor inhibitors induce sclerouveitis?]. J Fr Ophtalmol 2009;32:511-6
45. Volpe A, Caramaschi P, Carletto A, et al. Psoriasis onset during infliximab treatment: description of two cases. Rheumatol Int 2006;26:1158-60
46. Wendling D, Balblanc JC, Briancon D, et al. Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy. Joint Bone Spine 2008;75:315-8
47. Wollina U, Hansel G, Koch A, et al. Tumor necrosis factor-alpha inhibitorinduced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008;9:1-14